Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • BIOBUSINESS BRIEFS

Disruptions in the development of cell and gene therapies

  1. Guang Yang

    1. McKinsey and Company, Charlotte, NC, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Ling Liu

    1. McKinsey and Company, Summit, NJ, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Michelle Suhendra

    1. McKinsey and Company, Waltham, MA, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  4. Stuti Agarwal

    1. McKinsey and Company, Summit, NJ, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  5. Jeffrey F. Smith

    1. McKinsey and Company, Boston, MA, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Cell and gene therapies (CGTs), such as CAR-T cells, oligonucleotide therapies and viral-vector-based gene therapies, have the potential for substantial efficacy in treating diseases with high unmet needs. Reflecting this potential and the clinical validation of multiple CGT technology platforms, the number of industry-sponsored development programmes for CGTs has grown rapidly. However, anecdotally, there have been numerous reports of delays in development programmes for CGTs, reminiscent of the growing pains associated with the very early days of other therapeutic modalities such as monoclonal antibodies (mAbs).

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 21, 171 (2022)

doi: https://doi.org/10.1038/d41573-022-00004-6

Acknowledgements

The authors wish to thank Katarzyna Smietana, Edd Fleming, Lieven Van Der Veken and Matthias Evers for their discussions and contributions.

Supplementary Information

  1. Supplementary information

Competing Interests

The authors of this article are employees of McKinsey & Company, a management consultancy that works with organizations across the private, public and social sectors, including with the world’s leading biopharmaceutical and biotech companies on clinical development topics. The analysis in this study was funded by McKinsey’s Life Science practice and undertaken independently of any other organizations.

Nature Careers

Jobs

  • Postdoctoral Fellow

    The Dubal Laboratory of Neuroscience and Aging at the University of California, San Francisco (UCSF) seeks postdoctoral fellows to investigate the ...

    San Francisco, California

    University of California, San Francsico

  • Postdoctoral Associate

    Houston, Texas (US)

    Baylor College of Medicine (BCM)

  • Postdoctoral Research Fellow

    Description Applications are invited for a postdoctoral fellow position at the Lunenfeld-Tanenbaum Research Institute, Sinai Health, to participate...

    Toronto (City), Ontario (CA)

    Sinai Health

  • Postdoctoral Research Associate - Surgery

    Memphis, Tennessee

    St. Jude Children's Research Hospital (St. Jude)

  • Open Rank Faculty Position in Biochemistry and Molecular Genetics

    The Department of Biochemistry & Molecular Genetics (www.virginia.edu/bmg) and the University of Virginia Cancer Center

    Charlottesville, Virginia

    Biochemistry & Molecular Genetics

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links